FTI Advances is a leading toxicological certificate services provider in India — delivering ADE, PDE, OEL, HBEL, and ICH impurity certificates for global pharmaceutical manufacturers. Audit-ready. Regulatory-compliant. Fast turnaround.
Toxicological certificate services encompass the full range of formal toxicological assessments and documentation required by pharmaceutical manufacturers to demonstrate regulatory compliance, product safety, and worker protection. The core deliverable is a toxicological certificate — a formal document prepared and signed by a qualified toxicologist, stating a health-based exposure limit (such as ADE, PDE, or OEL) for a specific compound, based on a systematic review of available toxicological and pharmacological data.
These certificates are used in cleaning validation (to set residue limits for shared manufacturing equipment), occupational hygiene programmes (to set airborne exposure limits for workers), pharmaceutical impurity control strategies (for residual solvents, elemental impurities, and genotoxic impurities), and regulatory submissions to EMA, FDA, WHO, CDSCO, ANVISA, and other agencies.
The demand for toxicological certificate services has grown sharply since EMA's 2014 mandate on health-based exposure limits and India's revised Schedule M implementation — making professional toxicological certificate providers an essential partner for compliant pharmaceutical manufacturing.
As a comprehensive toxicological certificate services provider, FTI Advances offers the following certificate types for pharmaceutical manufacturers:
Any pharmaceutical organisation operating in a regulated environment needs toxicological certificate services at some point. The most common scenarios include: multi-product manufacturing facilities requiring ADE/PDE certificates for all APIs in their product portfolio; new product introductions where HBEL documentation must be established before manufacturing commences; regulatory submissions to EMA, FDA, or other agencies requiring HBEL documentation as part of the dossier; GMP re-inspections where deficiency letters cite missing or inadequate HBEL documentation; and HPAPI programme launches requiring OEL and containment strategy documentation.
In India specifically, the revised Schedule M compliance deadline has created urgent demand for toxicological certificate services among domestic API and FDF manufacturers who are now required to have documented HBELs for all shared-equipment products.
FTI Advances combines three core advantages that make it India's preferred toxicological certificate services provider: scientific excellence — our reports are prepared by toxicologists with deep expertise in pharmaceutical risk assessment, not template-generated summaries; regulatory breadth — every certificate simultaneously satisfies EMA, FDA, WHO-GMP, Schedule M, and PIC/S requirements; and operational efficiency — our streamlined process delivers standard certificates in 5–7 business days at competitive pricing.
We are incubated at the National Forensic Sciences University (NFSU), Ahmedabad — India's premier forensic and analytical sciences institution — giving us access to world-class scientific resources and academic expertise. This institutional backing provides an additional layer of credibility for our toxicological certificates in regulatory submissions and GMP audit documentation.
Under EMA Chapter 7 and WHO-GMP requirements, pharmaceutical manufacturers must qualify the suppliers from whom they receive critical GMP services — including toxicological certificate providers. FTI Advances provides a comprehensive supplier qualification package including company profile, quality management system documentation, toxicologist CV and credentials, conflict of interest declaration, and sample report format — enabling our clients to complete their supplier audit and qualification efficiently.
We also support on-site or remote supplier audits by client quality assurance teams, and can participate in regulatory agency audits where our toxicological certificates are under review — providing direct technical responses to inspector queries about our methodology and credentials.
Indian pharmaceutical companies exporting to the EU, USA, Canada, Australia, Japan, and other regulated markets face dual compliance requirements. FTI Advances' toxicological certificate services are specifically designed to satisfy all major regulatory frameworks simultaneously — meaning one certificate from our team covers EMA, FDA, TGA, PMDA, and Health Canada requirements without the need for separate reports per market.
This multi-framework approach significantly reduces the total cost of toxicological compliance for Indian export-oriented pharmaceutical manufacturers — a key competitive advantage of sourcing toxicological certificate services from an experienced Indian CRO like FTI Advances.
India is the world's largest generic pharmaceutical exporter, and Indian manufacturers face some of the most demanding regulatory requirements globally — simultaneously complying with domestic Schedule M, EMA GMP, USFDA, WHO-GMP, and often ANVISA or TGA requirements. FTI Advances has been purpose-built to serve this exact need — as a toxicological certificate services provider that understands both Indian pharmaceutical manufacturing realities and international regulatory expectations.
Our clients range from large multinational API manufacturers in Gujarat and Hyderabad to emerging biotech companies in Pune and Bengaluru. We provide toxicological certificate services india across all therapeutic categories — antibiotics, oncology, cardiovascular, CNS, hormonal, antifungal, and biological therapies. Our trusted toxicological certificate services provider India reputation is built on scientific rigour, transparent methodology, and a 100% track record of audit-ready reports.
As a toxicology certificate provider india incubated at NFSU Ahmedabad, we combine academic excellence with practical pharmaceutical industry experience. Our team has worked with companies preparing for WHO prequalification, EMA site inspections, USFDA PAIs, and CDSCO Schedule M audits — providing toxicological certificate services that stand up to the most rigorous regulatory scrutiny. Whether you need a single ADE certificate or a complete portfolio-wide HBEL programme, FTI Advances delivers with the quality and speed your business demands.
The most effective compliance programmes are built on consistent, long-term relationships with qualified scientific partners. FTI Advances functions not just as a report issuer but as an ongoing strategic partner — supporting new product introductions, managing periodic HBEL reviews as required by EMA Q&A 2018, responding to regulatory queries, and helping facilities stay ahead of evolving GMP requirements. As your dedicated toxicological certificate services provider, our team develops a deep understanding of your facility, your product portfolio, and your regulatory timeline — enabling proactive compliance management rather than reactive fire-fighting before inspections.
Indian pharmaceutical companies exporting to the EU, USA, UK, Australia, Canada, and Japan face a complex regulatory landscape — one that requires simultaneously satisfying the documentation expectations of multiple agencies. FTI Advances addresses this challenge directly by preparing certificates that are structured to satisfy EMA, FDA, TGA, Health Canada, and PMDA requirements within a single document. This means your facility can commission one assessment from a single toxicological certificate services provider and use it across all your target markets — dramatically reducing both cost and the administrative burden of managing multiple provider relationships. For export-oriented Indian pharmaceutical companies, this integrated approach is one of the most practical compliance advantages available.
Regulatory agencies and pharmaceutical quality teams increasingly scrutinise the credentials behind toxicological assessments. At FTI Advances, transparency is a core commitment. Every certificate we issue as a toxicological certificate services provider includes the full name, qualifications, and professional declaration of the responsible toxicologist — a standard that many providers in the market do not consistently meet. Our quality management system documentation, sample report formats, and standard operating procedures are available for review during client supplier qualification audits. This openness reflects our confidence in the scientific quality of our work and ensures that your regulatory submissions are backed by documentation that can withstand the most rigorous inspector scrutiny.
From ADE/PDE to OEL, MACO, and impurity assessments — FTI Advances covers every toxicological certificate your pharmaceutical facility needs. Audit-ready. Multi-regulatory compliant. Fast turnaround.
Get Your Certificate Today →Every toxicological certificate your pharmaceutical facility needs — from one trusted India-based provider.
Patient safety certificates for cleaning validation — satisfying EMA, FDA, WHO, and Schedule M simultaneously.
Worker safety certificates for HPAPI handling — OSHA, ACGIH, and ISPE SMEPAC compliant.
Q3C residual solvents, Q3D elemental impurities, and M7(R2) genotoxic impurity TTC assessments.
Cleaning validation acceptance criteria derived directly from your HBEL certificates.
ADE/PDE certification for biologics, biosimilars, and ATMPs using pharmacological activity methodology.
Mandatory EMA Q&A 2018 periodic review and renewal of all certificate types.
ADE and PDE certificates protect patients from cross-contamination in shared manufacturing equipment. OEL certificates protect manufacturing workers from hazardous airborne API exposure. All three are types of toxicological certificates issued by qualified toxicologists from HBEL assessments. FTI Advances provides all three certificate types.
FTI Advances employs qualified toxicologists with documented credentials in pharmaceutical toxicological risk assessment. We provide a full supplier qualification package for EMA Chapter 7 compliance. Our certificates have been accepted in EMA, USFDA, WHO-GMP, CDSCO, and ANVISA inspections.
Yes. Our experienced toxicologist team covers small molecule APIs, biologics/biosimilars, hormones, cytotoxics, HPAPIs, oncology compounds, steroids, antifungals, novel NCEs, residual solvents, elemental impurities, and genotoxic impurities.
Yes. We provide full post-issuance support including written responses to inspector queries about our certificates, supplementary scientific data packages, and participation in regulatory agency technical discussions where our certificates are under review.
Toxicological certificates compliant with